A Protein Subunit SARS-CoV-2 Vaccine Seems Likely

摘要

In a phase 1 Australian trial, SCB-2019, a SARS-CoV-2 vaccine candidate containing a trimericform of the spike protein, was immunogenic and well tolerated. Unlike the current SARS-CoV-2 mRNA and adenovirus vaccines, most earlier viral vaccines have employed killed virus, attenuated live virus, or protein platforms. Now, Australian and Chinese investigators report interim results of a placebo-controlled, partially industry-supported phase 1 trial of a SARS-CoV-2 vaccine containing a recombinant fusion protein, SCB-2019, that reflects the structure of the trimeric SARS-CoV-2 spike protein (S) in its pre-fusion form.